Julie Watson

Dr. Julie Watson

STEMCELL Technologies
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2009 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
ABAikaterini Bilitou
Aikaterini Bilitou
Julie WatsonJulie Watson
Julie Watson
AGAnton Gartner
Anton Gartner
SOShin-ichi Ohnuma
Shin-ichi Ohnuma

26 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Julie WatsonJulie Watson
Julie Watson
PSPhilip Sanders
Philip Sanders
RDRebecca Dunmore
Rebecca Dunmore
GRGuglielmo Rosignoli
Guglielmo Rosignoli
YJYvon Julé
Yvon Julé
DFDonna K. Finch
Donna K. Finch
Tissue stem cell exhaustion is a key hallmark of aging, and in this study, we characterised its manifestation in the distal lung. We compared the lungs of 3- and 22-month old mice. We examined the gross morphological changes in these lungs, the density and function of epithelial progenitor populations and the epithelial gene expression profile. Bronchioles became smaller in their cross-sectional area and diameter. Using long-term EdU incorporation analysis and immunohistochemistry, we found that bronchiolar cell density remained stable with aging, but inferred rates of bronchiolar club progenitor cell self-renewal and differentiation were reduced, indicative of an overall slowdown in cellular turnover. Alveolar Type II progenitor cell density and self-renewal were maintained per unit tissue area with aging, but rates of inferred differentiation into Type I cells, and indeed overall density of Type I cells was reduced. Microarray analysis revealed age-related changes in multiple genes, including some with roles in proliferation and differentiation, and in IGF and TGFβ signalling pathways. By characterising how lung stem cell dynamics change with aging, this study will elucidate how they contribute to age-related loss of pulmonary function, and pathogenesis of common age-related pulmonary diseases.

13 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
VPVasiliki Papadaki
Vasiliki Papadaki
KAKen Asada
Ken Asada
Julie WatsonJulie Watson
Julie Watson
TTToshiya Tamura
Toshiya Tamura
ALAlex Leung
Alex Leung
SOShin-ichi Ohnuma
Shin-ichi Ohnuma
Osteomodulin (OMD) and proline/arginine-rich end leucine repeat protein (PRELP) are secreted extracellular matrix proteins belonging to the small leucine-rich proteoglycans family. We found that OMD and PRELP were specifically expressed in umbrella cells in bladder epithelia, and their expression levels were dramatically downregulated in all bladder cancers from very early stages and various epithelial cancers. Our in vitro studies including gene expression profiling using bladder cancer cell lines revealed that OMD or PRELP application suppressed the cancer progression by inhibiting TGF-β and EGF pathways, which reversed epithelial–mesenchymal transition (EMT), activated cell–cell adhesion, and inhibited various oncogenic pathways. Furthermore, the overexpression of OMD in bladder cancer cells strongly inhibited the anchorage-independent growth and tumorigenicity in mouse xenograft studies. On the other hand, we found that in the bladder epithelia, the knockout mice of OMD and/or PRELP gene caused partial EMT and a loss of tight junctions of the umbrella cells and resulted in formation of a bladder carcinoma in situ-like structure by spontaneous breakdowns of the umbrella cell layer. Furthermore, the ontological analysis of the expression profiling of an OMD knockout mouse bladder demonstrated very high similarity with those obtained from human bladder cancers. Our data indicate that OMD and PRELP are endogenous inhibitors of cancer initiation and progression by controlling EMT. OMD and/or PRELP may have potential for the treatment of bladder cancer.